This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction
Donghua Xie1, Brian H. Annex1,
2, Craig F. Donatucci3
1Division of Cardiovascular Medicine and Department of Medicine,
2Division of Cardiology and Department of Medicine,
Duke University Medical Center, Durham, NC 27710, USA
3Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Abstract
The past decade has seen an explosion of new information on the physiology of penile erection, and
pathophysiology of erectile dysfunction (ED). Hypercholesterolemia is a chronic condition that can lead to degeneration in the
vasculature bed and can result in ED if the penile vasculature is involved. Angiogenesis is the growth of new blood
vessels from preexisting vasculature. Therapeutic angiogenesis seeks to harness the mechanisms of vascular growth
to treat disorders of inadequate tissue perfusion, such as coronary artery disease and ED. There have been
tremendous changes in the field of therapeutic angiogenesis over the past decade, and there is much promise for the future.
Initial preclinical work with cytokine growth factor delivery resulted in a great deal of enthusiasm for the treatment of
ischemic heart and/or peripheral vascular disease, though clinical studies have not achieved similar success. With an
increased understanding of the complex mechanisms involved in angiogenesis, novel therapies which target multiple
different angiogenic pathways are also being developed and tested. The penis is a convenient tissue target for gene
therapy because of its external location and accessibility, the ubiquity of endothelial lined spaces, and low level of
blood flow, especially in the flaccid state. Therapeutic angiogenesis is an exciting field that continues to evolve. This
review will focus on the development of growth factors for hypercholesterolemic ED, the use of various growth
factors for ED therapy, their routes of delivery, and the results in animal
studies. (Asian J Androl 2008 Jan; 10: 23_27)
Keywords: erectile dysfunction; hypercholesterolemia; angiogenic growth factors; nitric oxide synthase
Correspondence to: Dr Craig F. Donatucci, Box 3274, Duke University Medical Center Dur-ham, NC 27710, USA.
Tel : +1-919-684-2127 Fax: +1-919-681-7423
E-mail: donat001@mc.duke.edu
DOI: 10.1111/j.1745-7262.2008.00372.x
1 Introduction
The use of phosphodiesterase type 5 (PDE-5) inhibitors has a proven record of safety and efficacy in preclinical
and human trials for erectile dysfunction (ED) [1, 2]. However, there are approximately 30% of patients with ED in
whom PDE-5 inhibitors are not effective. The clinical efficacy of PDE-5 inhibitors is diminished in "difficult to trea"
patient groups [3, 4]. This prompts the development of new approaches, including gene-based therapies for the
treatment of ED.
Indeed the widespread use of the PDE inhibitors has resulted in an explosion of new information on the vascular
biology that underlies the physiology of erection and the pathophysiology of ED. Endothelial cell mediated
venous-occlusion, by vascular smooth muscles in the corpus cavernosum, became recognized as the principle event in
normal penile erection [5]. Nitric oxide (NO) has been shown to be the critical mediator of this endothelial/smooth
muscle cell interaction [5]. ED and atherosclerosis share many common risk factors [6]. Hypercholesterolemia is
one of the major risk factors for the development of ED; studies have shown that in men there is a 1.32-fold increase
in the risk of developing ED for every 1 nmol/L increase in cholesterol [6]. Moreover, there was high prevalence of
undiagnosed hypercholesterolaemia and hypertriglyceridaemia in men presenting with ED [7]. The induction of
endothelial cell dysfunction in the penile vasculature tissue using a hypercholesterolemic diet is also an established
model for evaluating the pathogenesis of ED [8_12].
Angiogenesis is defined as the growth and proliferation of blood vessels from pre-existing
vascular structures. Therapeutic angiogenesis seeks to harness the mechanisms of vascular growth to treat disorders of inadequate tissue
perfusion. There have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and
there is much promise for the future. Initial preclinical
work with cytokine growth factor delivery resulted in a
great deal of enthusiasm, even though clinical studies
conducted to date have failed to achieve the same level
of success [13]. A number of angiogenic growth factors,
including vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor (bFGF), have been shown
to be present in corporal tissue and can also act as
protective factors in the setting of any vascular injury, such
as ED [14_17]. The penis is a convenient tissue target
for gene therapy because of its external location and
accessibility, the ubiquity of endothelial lined spaces, and
low level of blood flow, especially in the flaccid state
[18]. This review will focus on the development of
growth factors in hypercholesterolemic models of ED,
the use of various growth factors being investigated for
ED therapy, their routes of delivery, and the results in
animal studies.
2 Angiogenic growth factor families
The most extensively studied angiogenic cytokines
are VEGF and bFGF. Both VEGF and bFGF are known to be present in the blood vessel wall and the proper
expression of these angiogenic growth factors is required
for normal blood vessel growth during embryonic
development [13, 16_17, 19_20]. In adult blood vessels,
VEGF can act as a survival factor for the
micro-vascular endothelium and VEGF can help endothelial cells avoid
cell death (apoptosis) when subject to injury [21_23].
Currently, the VEGF family consists mainly of VEGF-A,
VEGF-B, VEGF-C, VEGF-D, and VEGF-E. VEGF interacts with three subtypes of VEGF receptors occurring
on the cellular membrane known as VEGFR-1, -2, -3.
VEGFR-1, which binds VEGF-A, -B, acts as inhibitor of
angiogenesis; VEGFR-2, which binds VEGF-A, -C, and
-D, plays a critical role in angiogenesis; VEGFR-3, which
binds VEGF-C and -D, is important in lymphogenesis
[24]. Structurally, the VEGFs are related to the platelet
derived growth factor (PDGF) family of growth factors,
with intrachain and interchain disulfide bonds between
eight cysteine residues in conserved positions. The crystal
structure of VEGF-A revealed two monomers that are
organized in an anti-parallel fashion to form a dimer, with
the receptor-binding sites located at each pole of the
dimer[25]. The VEGFs preferentially form homodimers,
although VEGF-A and PDGF heterodimers have been
identified [26]. Alternative splicing of several of the VEGF
family members gives rise to splice variants with
different biological activities. The human splice variants are
denoted VEGF-A121, VEGF-A145,
VEGF-A165, VEGF-A189 and
VEGF-A206. The mouse splice variants are one
amino-acid residue shorter than the corresponding
human splice variants, and they are denoted
VEGF-A120 and so forth. The activities of the VEGFA splice variants are
dictated by their different abilities to interact with VEGFR
co-receptors, such as neuropilins and heparin sulfate
proteoglycans (HSPGs). Another splice variant of
VEGF-A, known as VEGF165b, has been proposed to negatively
regulate VEGFR activity, although whether this splice
variant is present in corporal tissue is unknown [27]. The
bioactivity of VEGF family members is also regulated by
proteolytic processing. This mechanism might enable
specific interactions with different types of receptor. For
example, in humans, processed VEGF-C and -D bind to
VEGFR-2, as well as to VEGFR-3. Furthermore, proteolytic processing of VEGFA splice variants affects their
ability to interact with the VEGF co-receptors HSPGs
and neuropilins [28]. When VEGF binds to its membrane receptor, the receptor becomes dimerized, it
autophosphorylates, and the receptor may then signal
through the phosphatidylinositol 3 kinase (PI3K)
pathway with activation/phosphorylation of Akt and
endothelial nitric oxide synthase (eNOS) [24, 29].
Basic FGF is an 18-kDa protein with a strong
affinity for heparin sulfate molecules on the cell surface and
in the extra-cellular matrix and bFGF binds to a family of
receptors found on multiple cell types [30]. FGF-2
interacts with specific cell surface receptor proteins
derived from at least four separate genes (FGFR1_4). A
number of splice variants exists for each receptor type
resulting in differing ligand binding domains. The splice
variants confer specificity in signaling in response to the
various FGF family members. FGF-2 has been proposed
to have two separate receptor binding sites, which might
allow a single FGF-2 to bind to two receptors or to
interact with a single receptor in two separate positions [31].
HSPGs can increase the affinity of FGF-2 for its
receptors [32] and potentially act as a bridge to facilitate the
dimerization of receptors. Indeed, a heparin-binding site
on FGFR1 has also been identified [31], providing
additional evidence that a ternary complex of FGF-2, HSPG
and receptor exist.
Vascular network formation requires several
endothelial cell growth factors working together. These
factors have a potent angiogenic effect, and their precise
coordination is essential for vascular development.
Among them, angiopoietins function through the Tie2
receptor, whose signaling is critical to regulate vascular
stabilization and remodeling. It has been reported that
the angiopoietin/Tie2 signal is involved in survival and
migration of endothelial cells and regulates vascular
remodeling and maintenance of vascular integrity [33]. This
remains an area of great interest that is underexplored.
Both VEGF and FGF are present in corporal tissue
[34_39]. One of the downstream effects of VEGF includes the phosphorylation and activation of Akt and
eNOS, which has been shown to mediate VEGF-induced
penile erection by further mediating activation of
guanosine 3', 5'-cyclic monophosphate (cGMP) and cyclic
GMP-dependent kinase (cGK-1) [25, 40].
3 Changes in expression of angiogenic growth
factors in hypercholesterolemic models of ED
Some studies have begun to look at the changes in
angiogenic growth factors in the setting of atraumatic
vascular injury. Azadzoi [41] and Wang et
al. [42] showed that in corporal tissue VEGFR-2 was decreased in
rabbits on 0.5% high cholesterol (HC) diet, while VEGF
was increased at early timepoints but decreased at late
timepoints. Ryu et al. [11] demonstrated that VEGF
(including mRNA levels of three VEGF splice variants
VEGF120, VEGF164, and
VEGF188) and VEGFR-2 were downregulated in rat corporal tissue with a 4% HC diet
for 3 months. Byrne et al. [14] and Xie
et al. [43] demonstrated decreased VEGF-A (including mRNA levels of 3
VEGF splice variants VEGF121,
VEGF165, and VEGF189) in corporal tissue of rabbits on 1% HC diet, which
developed at an early timepoint in their study. Thus,
differences in cholesterol content, duration of feeding, animal
species, and injury models may account for different
timing for VEGF decrease. Recent studies in skeletal muscle
have shown that changes in the VEGF receptor ligand
system can affect injury and repair [44].
4 Changes of NOS expression in hypercholesterolemic models of ED
Both neuronal and eNOS generate NO [45_49]. Activation of the central and peripheral nervous systems
leads to NO production from neuronal NOS (nNOS). The initiation of tumescence and reduction in nNOS play
an important role in ED [48, 49]. Initial tumescence is
produced by appropriately stimulated release of neuronal
nitric oxide, which is followed by an increase in eNOS
activity that alters intracorporal blood flow for the
further promotion of tumescence [49]. Xie et
al. [12], Lee et al. [28] and Ryu et
al. [11] demonstrated that Akt phosphorylation and eNOS phosphorylation were
downregulated in the corporal tissue of
hyperchoelsterolemic animals compared with that of control animals.
Xie et al. [12, 29] also report that a reduction of eNOS
phosphorylation was at Ser-1177 while no change at Thr
495 in the corporal tissue of hypercholesterolemic rabbit
or apolipoprotein E knockout (ApoE-/-) mice.
Interestingly total eNOS was higher in the
ApoE-/- mice (1.25% HC diet) than that of wild-type C57BL6 mice but not in
hyepercholesterolemic rabbits (1% HC diet) [12, 29]. Xie
et al. [12] and Lee et al. [28] also reported that changes
in nNOS occur as early as 4 weeks after the start of the
HC diet in hypercholesterolemic mice and rabbits.
Azadzoi et al. [42] found that cavernosal nNOS and
eNOS protein levels were unaffected at week 4 but were
significantly decreased at weeks 8 and 16 after the
induction of atherosclerosis by a 0.5% HC diet. Interestingly, they found inducible NOS (iNOS) protein
was markedly increased during the course of the induced
arterial disease [42]. Understanding the manner in which
angiogenic growth factors work in concert with changes
in NOS isoforms is an area of intense interest.
5 Therapeutic angiogenesis trials in
hypercholesterolemic models of ED
In the setting of vascular injury, angiogenic growth
factors can act as survival factors for the microvascular
endothelium [14, 17, 21]. Both VEGF protein and VEGF-DNA can be successfully delivered to the rat
penis [50]. Henry et al. [14] showed that VEGF had
beneficial effects on the structure and function of corporal
endothelial and smooth muscle cells in
hypercholesterolemic rabbits. Additionally, the effect of systemic
(intravenous) VEGF on corporal tissue was superior to
the effect of local intra-cavernously injected VEGF on
corporal tissue in restoring vasoreactivity [14, 15]. When
given exogenously VEGF causes an increase in vascular
permeability and a breakdown of the integrity of the
endothelium [51]. Combined gene transfer of both
ad-angiopoietin-1 and ad-VEGF165 has been shown to
significantly increase cavernous angiogenesis, eNOS
phosphorylation, and cGMP expression compared with
that in the groups treated with either therapy alone. Erectile
function, as evaluated by electrical stimulation of the
cavernous nerve 2 and 8 weeks after treatment, was
completely restored in the combined treatment group,
whereas intracavernous injection of either ad-Ang1 or
ad-VEGF165 alone elicited partial improvement [52].
In a preclinical model of hypercholesterolemic arterial injury,
intravenous bFGF was able to protect the arterial
endothelium [17]. However, bFGF also has the potential to
cause fibrosis and systemic bFGF has been shown to
cause drug-related toxicities, including proteinuria and
hypotension [53_55]. Dai et al. [56] found that
systemic low dose bFGF induces favorable histological
changes in the corpus cavernosum of hypercholesterolemic rabbits. In the same pre-clinical model of ED,
Xie et al. [15] showed that intracavernosal injection of
low dose of bFGF improved vasoreactivites and increased
nNOS expression. They also observed bFGF induced increased VEGF expression and eNOS phosphorylation
at Ser 1177 [16].
6 Summary and future directions
In preclinical hypercholesterolemic animal models,
VEGF, bFGF, and angiopoietin have shown their promising application in improving erectile function or
corporal vasoreactivity. Various routes of application may
bring different efficacies. Combined application of
angiogenic factors may enhance cavernous angiogenesis
synergistically and restore on erectile function by
reinforcing the endothelium both structurally and
functionally [52].
Further studies are needed to study potential
differential changes in VEGF family members, and the
potential mechanisms for bFGF to induce eNOS
phosphorylation and nNOS expression. On the therapeutic side, new
combined regimens such as VEGF+ brain-derived
neurotrophic factor, have shown efficacy in animals with
neurogenic impotence [48], and engineered transcription
factors haver peripheral artery disease [57]. These
results give us new directions therapeutic angiogenesis in
hypercholesterolemic ED.
References
1 Abbott D, Comby P, Charuel C, Graepel P, Hanton G, Leblanc B,
Lodola A, et al. Preclinical safety profile of sildenafil. Int J
Impot Res 2004; 16:498_504.
2 Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil
citrate (Viagra) demonstrate no increase in risk of myocardial
infarction and cardiovascular death compared with placebo. Int J
Clin Pract 2003; 57: 597_600.
3 Anderson PC, Gommersall L, Hayne D, Arya M, Patel HR. New
phosphodiesterase inhibitors in the treatment of erectile
dysfunction. Expert Opin Pharmacother 2004; 5: 2241_9.
4 Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH.
Diagnostic evaluation of the erectile function domain of the
International Index of Erectile Function. Urology 1999;
54:346_51.
5 Fournier G Jr, Juenemann KP, Lue TF, Tanagho EA. Mechanism
of venous occlusion during canine penile erection: an anatomic
demonstration. J Urol 1987; 137: 163_7.
6 Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair
SN. Total cholesterol and high-density lipoprotein cholesterol as
important predictors of erectile dysfunction [see comments].
Am J Epidemiol 1994; 140: 930_7.
7 Smith NJ, Sak SC, Baldo O, Eardley I. The prevalence of newly
diagnosed hyperlipidaemia in men with erectile dysfunction. BJU
Int 2007; 100: 357_61.
8 Azadzoi KM, Goldstein I. Erectile dysfunction due to
atherosclerotic vascular disease: the development of an animal model. J
Urol 1992; 147: 1675_81.
9 Kim JH, Klyachkin ML, Svendsen E, Davies MG, Hagen PO,
Carson CC 3rd. Experimental hypercholesterolemia in rabbits
induces cavernosal atherosclerosis with endothelial and smooth
muscle cell dysfunction. J Urol 1994; 151: 198_205.
10 Nehra A, Azadzoi KM, Moreland RB, Pabby A, Siroky MB, Krane
RJ, et al. Cavernosal expandability is an erectile tissue
mechanical property which predicts trabecular histology in an animal
model of vasculogenic erectile dysfunction. J Urol 1998; 159:
2229_36.
11 Ryu JK, Shin HY, Song SU, Oh SM, Piao S, Han JY,
et al. Downregulation of angiogenic factors and their downstream
target molecules affects the deterioration of erectile function in a
rat model of hypercholesterolemia. Urology 2006; 67:
1329_34.
12 Xie D, Odronic SI, Wu F, Pippen AM, Donatucci CF, Annex BH.
A mouse model of hypercholesterolemia induced erectile
dysfunction. J Sex Med 2007; 4 (4 Pt 1): 898_907.
13 Byrne RR, Henry GD, Rao DS, Huynh TT, Pippen AM, Annex
BH, et al. Vascular endothelial growth factor restores corporal
smooth muscle function in vitro. J Urol 2001; 165: 1310_5.
14 Henry GD, Byrne R, Hunyh TT, Abraham V, Annex BH, Hagen
PO, et al. Intracavernosal injections of vascular endothelial
growth factor protects endothelial dependent corpora cavernosal
smooth muscle relaxation in the hypercholesterolemic rabbit: a
preliminary study. Int J Impot Res 2000; 12; 334_9.
15 Xie D, Pippen AM, Odronic SI, Annex BH, Donatucci CF.
Intracavernosal basic fibroblast growth factor improves
vasoreactivity in the hypercholesterolemic rabbit. J Sex Med
2006; 3: 223_32.
16 Meurice T, Bauters C, Vallet B, Corseaux D, van Belle E, Hamon
M, et al. bFGF restores endothelium-dependent responses of
hypercholesterolemic rabbit thoracic aorta. Am J Physiol 1997;
272: H613_7.
17 Jones WS, Annex BH. Growth factors for therapeutic
angiogenesis in peripheral arterial disease. Curr Opin Cardiol 2007; 22:
458_63.
18 Kendirci M, Teloken PE, Champion HC, Hellstrom WJ,
Bivalacqua TJ. Gene therapy for erectile dysfunction: fact or
fiction? Eur Urol 2006; 50: 1208_22.
19 Huynh TT, Davies MG, Annex BH, Hagen PO. Tissue factor in
the pathobiology of vein grafts. In: Vascular Surgery:
Proceedings of the Third Congress of the Asian Vascular Society. Wang
ZG, editor. International Academic Publishers. 1998; 385_8.
20 Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W,
Folkman J. Angiogenesis inhibitors endostatin or TNP-470
reduce intimal neovascularization and plaque growth in
apolipoprotein E-deficient mice. Circulation 1999; 99:
1726_32.
21 Folkman J. Clinical applications of research on angiogenesis. N
Engl J Med 1995; 333: 1757_63.
22 Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V,
et al. Vascular endothelial growth factor regulates endothelial
cell survival through the phosphatidylinositol 3'-kinase/Akt
signal transduction pathway. J Biol Chem 1998; 273: 30336_43.
23 Kwak HJ, Lee SJ, Lee YH, Ryu CH, Koh KN, Choi HY,
et al. Angiopoietin-1 inhibits irradiation and mannitol-induced
apoptosis in endothelial cells. Circulation 2000; 101: 2317_24.
24 Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF
receptor signaling_in control of vascular function. Nat Rev Mol
Cell Biol 2006; 7: 359_71.
25 Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de
Vos AM. Vascular endothelial growth factor: crystal structure and
functional mapping of the kinase domain receptor binding site.
Proc Natl Acad Sci USA 1997; 94: 7192_7.
26 De Falco S, Gigante B, Persico MG. Structure and function of
placental growth factor. Trends Cardiovasc Med 2002; 12: 241_6.
27 Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L,
Pritchard-Jones RO, et al. VEGF165b, an inhibitory vascular endothelial
growth factor splice variant: mechanism of action,
in vivo effect on angiogenesis and endogenous protein expression. Cancer Res
2004; 64: 7822_35.
28 Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML.
Processing of VEGF-A by matrix metalloproteinases regulates
bioavailability and vascular patterning in tumors. J Cell Biol
2005; 169: 681_91.
29 Xie D, Kontos CD, Donatucci CF, Annex BH. Cholesterol
feeding reduces vascular endothelial growth factor signaling in rabbit
corporal tissues. J Sex Med 2005; 2: 634_40.
30 Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem
Cell Biol 2000; 32: 115_20.
31 Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An
essential heparin-binding domain in the fibroblast growth factor
receptor kinase. Science 1993; 259: 1918_21.
32 Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell
surface, heparin-like molecules are required for binding basic
fibroblast growth factor to its high affinity receptor. Cell 1991;
64: 841_8.
33 Morisada T, Kubota Y, Urano T, Suda T, Oike Y. Angiopoietins
and angiopoietin-like proteins in angiogenesis. Endothelium 2006;
13: 71_9.
34 Burchardt T, Burchardt M, Chen MW, Buttyan R, de la Taille A,
Shabsigh A, et al. Expression of VEGF splice variants 144/145 and
205/206 in adult male tissues. IUBMB Life. 1999; 48: 405_8.
35 Burchardt T, Burchardt M, Chen MW, Buttyan R, de la Taille A,
Shabsigh A, et al. Expression of messenger ribonucleic acid splice
variants for vascular endothelial growth factor in the penis of
adult rats and humans. Biol Reprod 1999; 60: 398_404.
36 Te AE, Santarosa RP, Koo HP, Buttyan R, Greene LA, Kaplan
SA, et al. Neurotrophic factors in the rat penis. J Urol 1994;
152: 2167_72.
37 Haraguchi R, Suzuki K, Murakami R, Sakai M, Kamikawa M,
Kengaku M, et al. Molecular analysis of external genitalia
formation: the role of fibroblast growth factor (Fgf) genes during
genital tubercle formation. Development 2000; 127: 2471_9.
38 Ogino Y, Suzuki K, Haraguchi R, Satoh Y, Dolle P, Yamada G.
External genitalia formation: role of fibroblast growth factor,
retinoic acid signaling, and distal urethral epithelium. Ann N Y
Acad Sci 2001; 948: 13_31.
39 Satoh Y, Haraguchi R, Wright TJ, Mansour SL, Partanen J,
Hajihosseini MK, et al. Regulation of external genitalia
development by concerted actions of FGF ligands and FGF receptors.
Anat Embryol (Berl) 2004; 208: 479_86.
40 Musicki B, Palese MA, Crone JK, Burnett AL. Phosphorylated
endothelial nitric oxide synthase mediates vascular endothelial growth
factor-induced penile erection. Biol Reprod 2004; 70: 282_9.
41 Azadzoi KM. Vasculogenic erectile dysfunction: beyond the
haemodynamic changes. BJU Int 2006; 97: 11_6.
42 Wang T, Soker S, Atala A, Siroky MB, Azadzoi KM. Alterations
in angiogenic growth factors and neuronal nitric oxide synthase
expression in chronic cavernosal ischemia. Int J Impot Res 2004;
16: 403_11.
43 Xie D, Thompson MA, Pippen AM, Waters RE, Donatucci CF,
Annex BH. Decreases in corporal vascular endothelial growth
factor expression precede vasoreactivity changes in cholesterol
fed rabbits. J Urol 2005; 173: 1418_22.
44 Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH.
Impaired angiogenesis after hindlimb ischemia in type 2 diabetes
mellitus: differential regulation of vascular endothelial growth
factor receptor 1 and soluble vascular endothelial growth factor
receptor 1. Circ Res 2007; 101: 948_56.
45 Andersson KE, Wagner G. Physiology of penile erection. Physiol
Rev 1995; 75: 191_236.
46 Burnett AL, Calvin DC, Silver RI, Peppas DS, Docimo SG.
Immunohistochemical description of nitric oxide synthase isoforms
in human clitoris. J Urol 1997; 158: 75_8.
47 Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile
function. Pharmacol Ther 2005; 106: 233_66.
48 Lin CS, Lue TF. Growth factor therapy and neuronal nitric oxide
synthase. Int J Impot Res 2004; 16 (Suppl 1): S38_9.
49 Burnett AL. Novel nitric oxide signaling mechanisms regulate the
erectile response. Int J Impot Res 2004; 16 (Suppl 1): S15_9.
50 Burchardt M, Burchardt T, Anastasiadis AG, Buttyan R, de la
Taille A, Shabsigh A, et al. Application of angiogenic factors for
therapy of erectile dysfunction: protein and DNA transfer of
VEGF 165 into the rat penis. Urology 2005; 66: 665_70.
51 Peters KG. Vascular endothelial growth factor and the
angiopoietins_working together to build a better blood vessel. Circ Res
1998; 83: 342_3.
52 Ryu JK, Cho CH, Shin HY, Song SU, Oh SM, Lee M,
et al. Combined angiopoietin-1 and vascular endothelial growth factor
gene transfer restores cavernous angiogenesis and erectile
function in a rat model of hypercholesterolemia. Mol Ther 2006; 13:
705_15.
53 Inoue Y, King TE, Barker E, Danilof E, Newman LS. Basic
fibroblast growth factor and its receptors in idiopathic
pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit
Care Med 2002; 166: 765_73.
54 Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast
growth factor expression in Peyronie's disease. J Urol 2001; 165:
419_23.
55 Cooper LT Jr, Hiatt WR, Creager MA, Regensteiner JG, Casscells
W, Isner JM, et al. Proteinuria in a placebo-controlled study of
basic fibroblast growth factor for intermittent claudication. Vasc
Med 2001; 6: 235_9.
56 Dai Q, Silverstein AD, Davies MG, Hagen PO, Donatucci CF,
Annex BH. Systemic basic fibroblast growth factor induces
favorable histological changes in the corpus cavernosum of
hypercholesterolemic rabbits. J Urol 2003; 170 (2 Pt 1): 664_8.
57 Kontos CD, Annex BH. Engineered transcription factors for
therapeutic angiogenesis. Curr Opin Mol Ther 2007; 9: 145_52.
|